Subscribe

2022 Year in Review - Multiple Myeloma

Patient and Caregiver Preferences for RRMM Treatment Should Be Considered Using Shared Decision-Making
Multiple Myeloma
2022 Year in Review - Multiple Myeloma
A discrete-choice experiment and best-worst scaling survey identified the most and least important multiple myeloma treatment characteristics to patients and their caregivers. Read More ›
Ciltacabtagene Autoleucel Shows Promising Results in Patients with Multiple Myeloma Who Have Experienced Early Clinical Relapse
Multiple Myeloma
2022 Year in Review - Multiple Myeloma
Cohort B of CARTITUDE-2 evaluated the safety and efficacy of cilta-cel in high-risk patients who experienced early clinical relapse to determine its use in earlier lines of therapy. Read More ›
Updated Results from IKEMA Demonstrate a Median PFS of Nearly 3 Years with Isa-Kd
Multiple Myeloma
2022 Year in Review - Multiple Myeloma
Updated results from the IKEMA trial show a superior benefit with isatuximab + carfilzomib and dexamethasone versus carfilzomib and dexamethasone alone in patients with RRMM. Read More ›
Addition of ASCT to Triplet Induction and Lenalidomide Maintenance to Progression: Results from the DETERMINATION Trial
Multiple Myeloma
2022 Year in Review - Multiple Myeloma
The addition of ASCT to triplet induction with lenalidomide, bortezomib, and dexamethasone (RVd) and lenalidomide maintenance resulted in significant PFS benefit versus RVd alone. Read More ›

Page 3 of 3


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Sign Up for The Oncology Nurse®‑APN/PA

Subscribe to receive the free, monthly TON print publication and TON weekly e‑newsletter.

Subscribe
© Amplity Health. All Rights Reserved. Privacy Policy.